SNTA - Upwards of 50M for Asia alone suggests a deal equivalent to what PCYC got. Is the Ganetespib potential equivalent to the potential of pci-765, a best in class monotherapy?
BTW today's SNTA presentation has a 5'th subgroup, LDH. Also the presentation indicates there are two subgroups that the p3 will focus on.